Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | REN | P00797 | 3/20 | 0.42 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 6/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168307 | 1.00 | ACE (0.42) | ACERENVSIRCD274FABP4 | |
| SCHEMBL23351171 | 0.94 | ACE (0.38) | ACERENVSIRCD274FABP4 | |
| SCHEMBL21168368 | 0.94 | ACE (0.43) | ACERENFABP4FABP5MME | |
| SCHEMBL21168349 | 0.94 | ACE (0.43) | ACERENFABP4FABP5MME | |
| SCHEMBL25476887 | 0.93 | VSIR (0.36) | ACERENVSIRCD274DPP4 | |
| SCHEMBL21168251 | 0.91 | ACE (0.40) | ACERENVSIRCD274FABP4 | |
| SCHEMBL21168250 | 0.91 | ACE (0.40) | ACERENVSIRCD274FABP4 | |
| SCHEMBL21999107 | 0.89 | ACE (0.40) | ACERENVSIRCD274FABP4 | |
| SCHEMBL21168347 | 0.88 | ACE (0.40) | ACERENVSIRCD274FABP4 | |
| SCHEMBL21168326 | 0.88 | ACE (0.46) | ACEMMEMMEL1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | ACE 4818/4885REN 4264/4885VSIR 2881/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885REN 4143/4885VSIR 2875/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885REN 4143/4885VSIR 2875/4885 |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | ACE 4810/4885REN 4116/4885VSIR 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.